| Doxepin Hydrochloride Dosages & Strengths | ||||
|---|---|---|---|---|
| Strength | Format | Route | Strength | Class |
| Doxepin Hydrochloride 10 mg | capsule | oral | 1.0 each | OTC |
| Doxepin Hydrochloride 150 mg | capsule | oral | 1.0 each | OTC |
| Doxepin Hydrochloride 75 mg | capsule | oral | 1.0 each | OTC |
| Doxepin Hydrochloride 100 mg | capsule | oral | 1.0 each | OTC |
| Doxepin Hydrochloride 50 mg | capsule | oral | 1.0 each | OTC |
| Doxepin Hydrochloride 25 mg | capsule | oral | 1.0 each | OTC |
| Doxepin Hydrochloride 10 mg/mL | concentrate | oral | 1.0 milliliter(s) | OTC |
Posted by petesaunders over 3 years ago
Taken it for years to help with the insomnia problems associated with Chronic Fatigue Syndrome. The undesireable (literally!)...
Posted by laura703 over 3 years ago
I orignally started taking 25 mg for chronic hives after a roller coaster w/any thing containing blue dye, prednizone, allegr...
Posted by cjmom over 4 years ago
I have been taking it for about a month now...25mg at bedtime...it does help me sleep. I am taking it for the itch associate...
NEWS | SAN DIEGO Somaxon submits new drug application - San Diego Daily Transcript (subscription)
... has submitted a new drug application (NDA) to the US Food and Drug Administration for Silenor (doxepin hydrochloride) for the treatment of insomnia. ...
Fri Feb 01 18:38:44 -0500 2008
Somaxon Pharmaceuticals Submits New Drug Application For SILENOR ... - Medical News Today (press release)
... reports or the FDA's findings of safety and efficacy for other formulations of doxepin hydrochloride that have previously been approved by the FDA. ...
Mon Feb 04 07:02:43 -0500 2008
Somaxon submits new drug application - San Diego Daily Transcript (subscription)
... has submitted a new drug application (NDA) to the US Food and Drug Administration for Silenor (doxepin hydrochloride) for the treatment of insomnia. ...
Fri Feb 01 18:38:42 -0500 2008
doxepin hydrochloride - A dibenzoxepin derivative and tricyclic antidepressant with antipruritic and sedative activities. Doxepin blocks the reuptake of norepinephrine and serotonin into presynaptic terminals thereby prolonging the availability of the monoaminergic neurotransmitters within the synaptic cleft and enhancing their action leading to sedative effects. Doxepin also has antagonistic effects on histamine (H1 and H2), 5-HT2, alpha-1 adrenergic, and muscarinic receptors. The antipruritic effect of this agent is the result mediated through inhibition of histamine receptors.